Talazoparib
Brand: Talzenna (global) / Talazoparib (IN/BD)
Anticancer
PARP inhibitor
Pharmacokinetics
| Half-life | 90 hours |
| Tmax | 1 h |
| Protein Binding | 74 % |
| Volume of Distribution | 1.9 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | no |
| Notes | Most potent PARP inhibitor; very low daily dose (1 mg/day). Reduce dose in renal impairment. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Anemia, neutropenia, thrombocytopenia, fatigue
Contraindications:
Severe renal impairment
Precautions:
CBC every 2–4 weeks initially; consider dose reduction based on toxicity
half-life ~90 hours (very long)
max dose = 1 mg/day (oral once daily)
→ significantly lower mg than other PARPs